(Q40584161)

21 September 2017

1 reference

title

Use of teicoplanin in community medicine (English)

1 reference

21 September 2017

A P Wilson

1

1 reference

21 September 2017

R N Grüneberg

series ordinal

2

1 reference

21 September 2017

publication date

1 September 1994

1 reference

European Journal of Clinical Microbiology & Infectious Diseases

21 September 2017

published in

1 reference

21 September 2017

volume

13

1 reference

21 September 2017

issue

9

1 reference

21 September 2017

page(s)

701-710

1 reference

Emergence of Enterococcus as a Significant Pathogen

21 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FBF02276052

Antimicrobial Resistance in Streptococcus pneumoniae: An Epidemiological Survey in France, 1970-1990

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02276052

A multicentre open clinical trial of teicoplanin in infections caused by gram-positive bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02276052

Teicoplanin pharmacokinetics in intravenous drug abusers being treated for bacterial endocarditis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02276052

A review of the safety profile of teicoplanin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02276052

Double-blind comparison of teicoplanin versus vancomycin in febrile neutropenic patients receiving concomitant tobramycin and piperacillin: effect on cyclosporin A-associated nephrotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02276052

Evaluation of teicoplanin for treatment of endocarditis caused by gram-positive cocci in 20 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02276052

Teicoplanin in the treatment of gram-positive-bacterial endocarditis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02276052

Failure of treatment with teicoplanin at 6 milligrams/kilogram/day in patients with Staphylococcus aureus intravascular infection. The Infectious Diseases Consortium of Oregon

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02276052

Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02276052

Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02276052

Randomized prospective study comparing vancomycin with teicoplanin in the treatment of infections associated with Hickman catheters

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02276052

Randomized study of vancomycin versus teicoplanin for the treatment of gram-positive bacterial infections in immunocompromised hosts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02276052

Methicillin-resistant Staphylococcus aureus in Europe

21 January 2018

1 reference

12 December 2020

Comparison of intravenous teicoplanin with intramuscular amoxycillin for the prophylaxis of streptococcal bacteraemia in dental patients.

1 reference

12 December 2020

Feasible and desirable future targets for reducing the costs of hospital infections

1 reference

12 December 2020

Dosage recommendations for teicoplanin

1 reference

12 December 2020

Teicoplanin in home therapy of the terminally ill child.

1 reference

12 December 2020

Pharmacokinetics of teicoplanin in subjects with varying degrees of renal function

1 reference

12 December 2020

An office model of outpatient parenteral antibiotic therapy

1 reference

12 December 2020

Home intravenous antibiotic therapy: a team approach

1 reference

12 December 2020

A prospective study comparing vancomycin and teicoplanin as second-line empiric therapy for infection in neutropenic patients

1 reference

12 December 2020

Teicoplanin administration in patients experiencing reactions to vancomycin

1 reference

12 December 2020

Cost containment associated with decreased parenteral antibiotic administration frequencies.

1 reference

12 December 2020

Cross-infection and its prevention

1 reference

12 December 2020

Treating bone and joint infections with teicoplanin: hospitalization vs outpatient cost issues

1 reference

12 December 2020

Teicoplanin--domiciliary use in surgical infections

1 reference

12 December 2020

Cost-effectiveness of outpatient parenteral antibiotics: a review of the literature

1 reference

12 December 2020

Pharmacokinetics of teicoplanin upon multiple dose intravenous administration to normal healthy male volunteers

1 reference

12 December 2020

Single daily dose treatment of severe refractory infections with ceftriaxone. Cost savings and possible parenteral outpatient treatment.

1 reference

12 December 2020

Cost implications of malpractice and adverse events.

1 reference

12 December 2020

Human and non-financial costs of hospital-acquired infection

1 reference

12 December 2020

Intravenous antibiotic therapy in an outpatient setting

1 reference

12 December 2020

Outpatient use of ceftriaxone: a cost-benefit analysis

1 reference

12 December 2020

The efficacy of teicoplanin in the treatment of endocarditis caused by gram-positive bacteria

1 reference

12 December 2020

Clinical pharmacokinetics of teicoplanin

1 reference

12 December 2020

The true cost of monitoring antibiotic levels

1 reference

12 December 2020

Teicoplanin in the treatment of bone and joint infections. Teicoplanin Bone and Joint Cooperative Study Group, USA

1 reference

12 December 2020

Cost effectiveness of teicoplanin and ceftriaxone: a once-daily antibiotic regimen

1 reference

12 December 2020

Impact of nosocomial infections on hospital costs.

1 reference

12 December 2020

The management of infections and antibiotic therapy: a European survey

1 reference

12 December 2020

Cost implications of home care on serious infections.

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF02276052

1 reference

Dimensions Publication ID

21 September 2017

1045433293

0 references

1 reference